Deborah L White

Summary

Affiliation: South Australia
Country: Australia

Publications

  1. request reprint
    White D, Saunders V, Lyons A, Branford S, Grigg A, To L, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 2005;106:2520-6 pubmed
    ..The IC50imatinib potentially provides a new prognostic indicator for molecular response in patients treated with imatinib. ..
  2. request reprint
    White D, Saunders V, Dang P, Engler J, Zannettino A, Cambareri A, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108:697-704 pubmed
    ..Determining interpatient and interdrug differences in cellular uptake and retention could allow individual optimization of kinase inhibitor therapy. ..
  3. White D, Dang P, Engler J, Frede A, Zrim S, Osborn M, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28:2761-7 pubmed publisher
    ..Early dose-intensity may reduce the negative prognostic impact of low OA. We propose that OA could be used to individualize dosage strategies for patients with CML to maximize molecular response and optimize long-term outcome. ..
  4. request reprint
    White D, Saunders V, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064-72 pubmed
    ..This pretherapy assay identifies patients at greatest risk of suboptimal response where dose intensity is critical, and those likely to respond equally well to standard dose imatinib. ..